Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
Fate Therapeutics Inc Logo

ARKG Holdings of Fate Therapeutics (FATE) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
September 8, 2021BUY550100.05%ARKG
September 3, 2021BUY748500.06%ARKG
August 31, 2021BUY622660.0534%ARKG
August 27, 2021BUY578410.0509%ARKG
August 24, 2021BUY1718400.1497%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKGARKK$64.81
⚖️Weighting🧢Market Cap
4.02%$6.17b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
5128.5
🏋️‍♀️Weight Rank Across All Funds🌏Country
18🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$47.845.15%
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...